As this happened, H.C. Wainwright downgraded its Sutro Biopharma Inc [STRO] rating to a Neutral from a a Buy in a research note published recently. A number of analysts have revised their coverage, including Wedbush’s analysts, who decreased its forecast for the stock in mid March from “an Outperform” to “a Neutral”. Citizens JMP also remained covering STRO and has decreased its forecast on March 14, 2025 with a “Mkt perform” recommendation from previously “Mkt outperform” rating. BofA Securities revised its rating on March 14, 2025. It rated STRO as “an Underperform” which previously was an “a Buy”.
Price Performance Review of STRO
On Monday, Sutro Biopharma Inc [NASDAQ:STRO] saw its stock fall -0.17% to $0.87. Over the last five days, the stock has lost -17.14%. Sutro Biopharma Inc shares have fallen nearly -52.72% since the year began. Nevertheless, the stocks have fallen -79.67% over the past one year. While a 52-week high of $5.17 was reached on 01/24/25, a 52-week low of $0.52 was recorded on 04/17/25. SMA at 50 days reached $0.8932, while 200 days put it at $2.5100.
Levels Of Support And Resistance For STRO Stock
The 24-hour chart illustrates a support level at 0.8176, which if violated will result in even more drops to 0.7652. On the upside, there is a resistance level at 0.9612. A further resistance level may holdings at 1.0524. The Relative Strength Index (RSI) on the 14-day chart is 48.45, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.0849, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 77.19%. Stochastics %K at 39.69% indicates the stock is a holding.
The most recent change occurred on May 08, 2024 when BofA Securities began covering the stock and recommended ‘”a Buy”‘ rating along with a $12 price target.
